• U.S. FDA clearance for IQ-UIP, an AI-driven diagnostic tool for Interstitial Pulmonary Fibrosis
• Unveiled CT:VQ, a non-radioactive alternative to traditional Nuclear VQ scans
• Expanded presence in leading U.S. medical institutions and the Australian market

4DMedical Limited (ASX:4DX) reported several key milestones in its 1H FY2025 investor presentation, including U.S. FDA clearance for its IQ-UIP AI-driven diagnostic tool for Interstitial Pulmonary Fibrosis, and the unveiling of its CT:VQ imaging solution, a non-radioactive alternative to traditional Nuclear VQ scans. The company also expanded its presence in leading U.S. medical institutions, such as the University of Chicago Medicine and UC San Diego Health, and significantly grew its footprint in the Australian market through new contracts with Qscan and Perth Radiological Clinic. 4DMedical's SaaS revenue showed strong momentum, with a 16.5% underlying growth in 1H FY2025 compared to the previous half, driven by a 41% increase in global sites and a 77% growth in scan volumes. The company also reported a strong focus on cost control, with net operating expenses down 11% compared to the prior half. To fund its commercialization efforts and working capital requirements, 4DMedical launched a capital raise, including a placement to institutional investors and an underwritten share purchase plan for eligible shareholders.

The company expects to achieve several significant milestones in 2025, including continued engagement with the U.S. Department of Defense, growing its footprint of credible reference sites, showcasing the clinical outcomes of its CT:VQ solution at RSNA, and activating its reseller agreement with Philips.